IL-17 and limits of success

Zahra Omidian, Rizwan Ahmed, Adebola Giwa, Thomas Donner, Abdel Rahim A. Hamad

Research output: Contribution to journalArticlepeer-review


Interleukin-17 (IL-17) is a potent proinflammatory cytokine that protects a host against fungal and extracellular bacterial infections. On the other hand, excessive or dysregulated production of IL-17 underlines susceptibility to autoimmune disease. Consequently, blocking IL-17 has become an effective strategy for modulating several autoimmune diseases, including multiple sclerosis (MS), psoriasis, and rheumatoid arthritis (RA). Notably, however, IL-17 blockade remains ineffective or even pathogenic against important autoimmune diseases such as inflammatory bowel disease (IBD). Furthermore, the efficacy of IL-17 blockade against other autoimmune diseases, including type 1 diabetes (T1D) is currently unknown and waiting results of ongoing clinical trials. Coming years will determine whether the efficacy of IL-17 blockade is limited to certain autoimmune diseases or can be expanded to other autoimmune diseases. These efforts include new clinical trials aimed at testing second-generation agents with the goal of increasing the efficiency, spectrum, and ameliorating side effects of IL-17 blockade. Here we briefly review the roles of IL-17 in the pathogenesis of selected autoimmune diseases and provide updates on ongoing and recently completed trials of IL-17 based immunotherapies.

Original languageEnglish (US)
Pages (from-to)33-40
Number of pages8
JournalCellular Immunology
StatePublished - May 2019


  • Autoimmune diseases
  • Clinical trials
  • IL-17
  • Immunotherapy
  • Interleukin-17

ASJC Scopus subject areas

  • Immunology


Dive into the research topics of 'IL-17 and limits of success'. Together they form a unique fingerprint.

Cite this